With talks underway between the central authorities and Zydus Cadila over the pricing of the COVID-19 vaccine ZyCov-D, the pharma firm is learnt to have proposed a value of Rs 1,900 for its three-dose jab that may be given to these above 12 years of age.
Nonetheless, the federal government is negotiating for a discount in value and a ultimate determination on it’s prone to be taken this week, sources within the know of the developments informed PTI.
The federal government had on Thursday mentioned that the indigenously-developed, world’s first DNA-based needle-free COVID-19 vaccine by Zydus Cadila can be launched within the nationwide anti-coronavirus vaccination drive shortly.
“The corporate has proposed a value of Rs 1,900 inclusive of taxes for its three-dose jab.
“Negotiations are on. The corporate has been requested to rethink all of the features relating to the price of the vaccine. A ultimate determination on the worth of the vaccine is prone to be taken this week,” a supply mentioned.
One other supply mentioned the ZyCoV-D must be otherwise priced than Covaxin and Covishield as, other than being a three-dose vaccine, there’s a needle-free jet injector used for administering the vaccine that prices Rs 30,000.
That jet injector can be utilized for administering round 20,000 doses.
The vaccine is to be given on days zero, 28 and 56.
In response to sources, round three rounds of conferences have taken place to this point between the Centre and the corporate, the final one on Thursday.
In the meantime, the ministry can be ready for the suggestions from the Nationwide Technical Advisory Group on Immunisation (NTAGI ) for introducing ZyCoV-D within the inoculation drive and prioritising beneficiaries specializing in these aged 12-18 years with comorbidities.
The NTAGI will present the protocol and framework for the introduction of this vaccine within the COVID-19 immunisation drive, an official supply mentioned.
So far as the worth of the vaccine at which it will likely be procured is anxious, Union Well being Secretary Rajesh Bhushan, at a press convention on Thursday, mentioned the federal government is in dialog with the producers.
“Since this can be a three-dose vaccine and comes with a needleless supply system, it might have a differential pricing than the prevailing vaccines that are getting used within the COVID vaccination programme,” he mentioned.
The vaccine ZyCoV-D obtained Emergency Use Authorisation from the drug regulator on August 20 making it the primary vaccine to be administered within the age-group of 12 to 18 moreover adults.
Vaccines Covishield, Covaxin and Sputnik V are being given to solely these above 18 years of age and in contrast to ZyCoV-D, these are two-dose vaccines.
(Solely the headline and movie of this report could have been reworked by the Enterprise Normal employees; the remainder of the content material is auto-generated from a syndicated feed.)